Market Executive Summary

The global Viral Vector and Plasmid DNA market size is expected to reach US$ 2327.4 million by 2029, growing at a CAGR of 19.3% from 2023 to 2029.

Viral vectors carry genetic material into cells by exploiting the molecular mechanisms by which viruses transmit their genomes to other cells for infection.It can occur in vivo or in vitro.Plasmid carriers are plasmids artificially constructed on the basis of natural plasmids to adapt to laboratory operations.In recent years, global viral vector and plasmid DNA manufacturing has developed rapidly, with a compound growth rate of about 28% during 2018-2028.

In 2018, global sales of viral vector and plasmid DNA production reached $381 million. In 2018, China accounted for about 4% of global sales.In the next five years, the production of viral vectors and plasmid DNA products in China will continue to grow rapidly.Viral vector and plasmid DNA manufacturing are mainly divided into viral vector manufacturing and plasmid DNA manufacturing, among which viral vector manufacturing accounts for the largest proportion, accounting for nearly 38% of the total market in 2018. Viral vector and plasmid DNA manufacturing is mainly used for drug development and production of cancer, genetic diseases, viral infections and other diseases, among which cancer is the main application field, accounting for 35% in 2018.

The market is mainly driven by the significant applications of Viral Vector and Plasmid DNA in various end use industries. The expanding demands from the Cancer, Virus Infection and Hereditary Disease,, are propelling Viral Vector and Plasmid DNA market. Plasmid DNA, one of the segments analysed in this report, is projected to record CAGR and reach US$ million by the end of the analysis period. Growth in the Viral Vector segment is estimated at CAGR for the next seven-year period.

Global Viral Vector and Plasmid DNA key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.

North America is the largest market, with a share about 50%, followed by Europe, and Asia-Pacific, both have a share over 40 percent. 

In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections, etc.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide

1) Global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends;

2) Global market share and ranking by company;

3) Comprehensive presentation of the global market for Viral Vector and Plasmid DNA, with both quantitative and qualitative analysis through detailed segmentation;

4) Detailed value chain analysis and review of growth factors essential for the existing market players and new entrants;

5) Emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Viral Vector and Plasmid DNA market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Viral Vector and Plasmid DNA market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Viral Vector and Plasmid DNA sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Viral Vector and Plasmid DNA covered in this report include Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector, Lonza, BioReliance, MolMed, FUJIFILM Diosynth Biotechnologies and UniQure, etc.

The global Viral Vector and Plasmid DNA market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

    Brammer Bio

    Oxford BioMedica

    Cobra Biologics

    FinVector

    Lonza

    BioReliance

    MolMed

    FUJIFILM Diosynth Biotechnologies

    UniQure

    Aldevron

    Richter-Helm

    Eurogentec

    OBiO Technology

    Yposkesi

    Cell and Gene Therapy Catapult

    MassBiologics

    Biovian

    VGXI

    Gene Synthesis

    PlasmidFactory

    Jikai Gene

Global Viral Vector and Plasmid DNA market, by region:

    North America (U.S., Canada, Mexico)

    Europe (Germany, France, UK, Italy, etc.)

    Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

    South America (Brazil, etc.)

    Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Viral Vector and Plasmid DNA market, Segment by Type:

    Plasmid DNA

    Viral Vector

Global Viral Vector and Plasmid DNA market, by Application

    Cancer

    Virus Infection

    Hereditary Disease

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter Four: Detailed analysis of Viral Vector and Plasmid DNA companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.

Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter Twelve: Research Finding/Conclusion

Related Report:

Lentiviral Production System Market insights, Size, Share, Trends and Sales Trends 2030